Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
GMP Human IFN-gamma Protein (Cat. No. GMP-IFGH24) inhibits the proliferation of HT-29 cells. The specific activity of GMP Human IFN-gamma Protein is > 2.00×10^7 IU/mg, which is calibrated against human interferon gamma Standard (NIBSC code: 87/586) (QC tested).
Human IFN-gamma, premium grade (Cat. No. IFG-H4211) inhibits the proliferation of HT-29 cells. The specific activity of Human IFN-gamma, premium grade is > 2.00×10^7 IU/mg, which is calibrated against human interferon gamma Standard (NIBSC code: 87/586) (QC tested).
Biotinylated Monoclonal Anti-IFNγ Antibody, Mouse IgG1 (13E6H6) (Cat. No. IFN-BS138) captured on CM5 chip via anti-mouse antibodies surface can bind Human IFN-gamma, premium grade (Cat. No. IFG-H4211) with an affinity constant of 1.28 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Monoclonal Anti-IFNγ antibody, Mouse IgG2a (8C5F8) (Cat. No. IFN-S120) captured on CM5 chip via anti-mouse antibodies surface can bind Human IFN-gamma, premium grade (Cat. No. IFG-H4211) with an affinity constant of 0.933 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Cadi-05 | Cadi-05 | Approved | National Institute Of Allergy And Infectious Diseases (Niaid) | Immuvac, Leprovac, Mycidac-C | India | Carcinoma, Non-Small-Cell Lung; Leprosy | null | 1998-01-01 | Leprosy; Carcinoma, Non-Small-Cell Lung | Details |
Emapalumab | NI-0501 | Approved | Novimmune Sa | Gamifant | United States | Lymphohistiocytosis, Hemophagocytic | Novimmune Sa | 2018-11-20 | Macrophage Activation Syndrome; Still's Disease, Adult-Onset; Rare Diseases; Immune System Diseases; Arthritis, Juvenile; Lupus Erythematosus, Systemic; Lymphohistiocytosis, Hemophagocytic | Details |
Thalidomide | NSC-66847; NSC-527179; K-17; VP-02; FPF-300; FPF300 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Mainland China | Leprosy, Lepromatous; Multiple Myeloma | Changzhou Pharmaceutical Factory | 1982-01-01 | HIV Wasting Syndrome; Angiodysplasia; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Osteosarcoma; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Erythema Nodosum; Drug Resistant Epilepsy; Xerostomia; Sarcoma; Pancreatitis, Chronic; Adenocarcinoma, Clear Cell; Lymphoma, Follicular; Arachnoiditis; Carcinoma, Adenosquamous; Gastrointestinal Hemorrhage; Cholangitis, Sclerosing; Prostatic Neoplasms; Pelvic Pain; Neoplasm Metastasis; Stomatitis; Burning Mouth Syndrome; Mycobacterium avium-intracellulare Infection; Amyotrophic Lateral Sclerosis; Melanoma; Myelodysplastic-Myeloproliferative Diseases; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Vascular Malformations; Tuberculosis; Appendiceal Neoplasms; Lymphoma, Non-Hodgkin; Uterine Neoplasms; Anemia, Sideroblastic; Glioma; Leprosy, Lepromatous; Endometrial Neoplasms; Lung Neoplasms; Waldenstrom Macroglobulinemia; Kidney Neoplasms; Thalassemia; Carcinoid Tumor; Lupus Erythematosus, Discoid | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Tadekinig alfa (AB2 Bio) | Phase 3 Clinical | Ab2 Bio Ltd | Macrophage Activation Syndrome; Cytokine Release Syndrome; Lymphohistiocytosis, Hemophagocytic | Details | |
PDS-0101 | PDS-0101B; PDS-0101C; PDS-0101; PDS-0101A; PDS-101 | Phase 2 Clinical | Pds Biotechnology Corporation, Merck Serono | Head and Neck Neoplasms; Anus Neoplasms; Papillomavirus Infections; Vulvar Neoplasms; Oropharyngeal Neoplasms; Carcinoma, Squamous Cell; Uterine Cervical Neoplasms | Details |
YH-32367 | ABL105; YH-32367 | Phase 2 Clinical | Abl Bio Inc | Solid tumours; Stomach Neoplasms; Breast Neoplasms | Details |
OCH-NCNP1 | OCH-NCNP1 | Phase 2 Clinical | Keio University | Multiple Sclerosis; Crohn Disease | Details |
KIO-101(Kiora) | PP-001; KIO-101 | Phase 2 Clinical | 4sc Ag | Dry Eye Syndromes; Eye Diseases; Keratoconjunctivitis; Uveitis; Xerophthalmia; Conjunctival Diseases | Details |
ASN-002 (Ascend Biopharmaceuticals) | TG-1042; Ad-IFNγ; SP-002 (Ascend Biopharmaceuticals) | Phase 2 Clinical | Transgene Sa | Solid tumours; Lymphoma, B-Cell; Carcinoma, Basal Cell; Skin Neoplasms; Basal Cell Nevus Syndrome; Melanoma | Details |
IFN-gamma-secreting HAdV antigen specific T cells (Case Comprehensive Cancer Center) | Phase 1 Clinical | Case Comprehensive Cancer Center | Hematopoietic stem cell transplantation (HSCT) | Details | |
Recombinant human interferon gamma adenovirus injection (Guangzhou Dabo Biological Products) | Phase 1 Clinical | Guangzhou Dabo Biological Products Co Ltd | Liver Neoplasms; Nasopharyngeal Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details | |
EI-001 | EI-001 | Phase 1 Clinical | Elixiron Immunotherapeutics Inc | Vitiligo | Details |
This web search service is supported by Google Inc.